MedTrace Logo

A Single Ascending Dose Study of AV-006 in Healthy Subjects

NCT03931876 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2019-05-01

No results posted yet for this study

Summary

Characterization of the single dose pharmacokinetics of AV-006 in healthy male and female subjects. Description of safety and tolerability of AV-006 in healthy subjects

Conditions

Interventions

DRUG

Placebos

Single ascending dose administration

DRUG

AV-006

Single ascending dose administration

Sponsors & Collaborators

  • Arixa Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Jason Lickliter, PhD · Nucleus Network

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-06-24
Primary Completion
2019-09-01
Completion
2019-11-01

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03931876 on ClinicalTrials.gov